Patents
The invention provides an improved synthesis of enantiomerically pure Alkyl (Methyl or Ethyl) (S)-4-Bromo-3-hydroxybutanoate been achieved. The synthetic strategy features use of D-erythronolactone as the starting substrate. Its ready conversion to Alkyl 2,4-dibromo-3-hydroxybutanoate and selective C-2 debromination affords optically pure Alkyl (,S')-4-Bromo-3-hydroxybutanoate. The title compound is a key intermediate in arriving at the substrates for HMG-coA reductase inhibitors.